The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 05, 2019

Filed:

Feb. 17, 2016
Applicant:

Mayo Foundation for Medical Education and Research, Rochester, MN (US);

Inventors:

Matthew P. Goetz, Rochester, MN (US);

Judy C. Boughey, Rochester, MN (US);

Liewei Wang, Rochester, MN (US);

Krishna R. Kalari, Rochester, MN (US);

Richard M. Weinshilboum, Rochester, MN (US);

Vera J. Suman, St. Charles, MN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/06 (2006.01); A61K 31/337 (2006.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 31/337 (2013.01); A61K 45/06 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57415 (2013.01); G01N 33/57484 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01); G01N 2800/52 (2013.01);
Abstract

This document provides methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) is likely to respond to chemotherapy (e.g., a taxane therapy) based at least in part on the presence of a variant in the mammal's polycystic kidney disease gene 1 (PKD1) are provided. In addition, methods and materials involved in treating mammals having cancer (e.g., breast cancer) by administering an inhibitor of ubiquitin specific peptidase 2 (USP2) polypeptide activity (e.g., NSC-632839, a 2-cyano-pyrimidine, or a 2-cyano-triazine) in combination with another chemotherapeutic agent such as a taxane therapy are provided.


Find Patent Forward Citations

Loading…